Drug Profile
Antibody based therapeutics - Celgene/Sutro Biopharma
Alternative Names: Bispecific antibody - Celgene/SutroLatest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator Celgene Corporation; Sutro Biopharma
- Developer Bristol-Myers Squibb; Celgene Corporation; Sutro Biopharma
- Class Bispecific antibodies; Immunotherapies
- Mechanism of Action CD223 antigen inhibitors; CD3 antigen inhibitors; HAVCR2 protein inhibitors; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
- Preclinical Cancer
Most Recent Events
- 23 Feb 2022 Preclinical and phase I development is ongoing USA (Bristol Myers Squibb pipeline, February 2022)
- 23 Feb 2022 Phase-I clinical trials in Multiple myeloma in USA (Bristol Myers Squibb pipeline, February 2022)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)